EVO earnings

Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda

HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G

HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 14 August 2024Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-public

CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTERSTRONG START WITH JUST - EVOTEC BIOLOGICS IN Q1 2024POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEARRESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEGMENTS INTRODUCED: SHARED R&D AND JUST - EVOTEC BIOLOGICSHAMBURG, GERMANY / ACCESSWIRE / May 22, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced financial results and corporate updates for the first quarter 2024.HIGHLIGHTSEVOTEC'S TRANSACTIONAL BUSINESS IMPACTED BY HEADWINDS; STRONG GROWTH IN JUST - EVOTEC BIO

HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first quarter of 2024 on Wednesday, 22 May 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast details Date: Wednesday, 22 May 2024 Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link .The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications

FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCEPRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 MEVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST - EVOTEC BIOLOGICS” STARTING Q1 2024 HAMBURG, GERMANY / ACCESSWIRE / April 24, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.CONTIN

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 24 April 2024 Time: 3.00 pm CEST (02.00 pm BST, 09.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com.Conference call detailsTo join via phone, please pre-register

HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.During the call, the Chairwoman of Evotec's Supervisory Board, Prof. Iris Löw-Friedrich and Evotec's CEO Dr Mario Polywka will offer the Company's perspective on its commitment to comply with highest Corporate Governance standards and its dedication to well-balanced and transparent communication to all market participants. The statement will be limited to Evotec's scope of influence.Dr Mario Polywka will also share management's conviction to execute on

CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETSPARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERSPIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATIONALL ELEMENTS OF GUIDANCE CONFIRMEDHAMBURG, GERMANY / ACCESSWIRE / November 8, 2023 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced the financial results and corporate updates for the first nine months 2023.HIGHLIGHTSEVOTEC'S TOPLINE SUCCESS REFLECTS STRONG DEMANDGroup revenues increased by 14% (19% excluding fx-effects) to € 580.1 m (9M 2022: € 510.8 m); excluding a lower contribution from milestones, upfronts and license payments, Base business at € 575.3 m (9M 2022: € 502.8

Evotec SE / Key word(s): Miscellaneous Evotec SE to announce results for the first nine months 2023 on 08 November 2023 01.11.2023 / 12:05 CET/CESTThe issuer is solely responsible for the content of this announcement. Hamburg, Germany, 01 November 2023:Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first nine months 2023 on Wednesday, 08 November 2023.The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Webcast detailsDate: Wednesday, 08 November 2023Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the a

NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIALNEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMEDHAMBURG, GERMANY / ACCESSWIRE / August 29, 2023 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced its financial results and corporate updates for the first half-year of 2023.HIGHLIGHTSQ2 CYBER-INCIDENT TEMPORARILY REDUNCING STRONG ORGANIC REVENUE GROWTHGroup revenues increased by 14% to € 383.8 m (H1 2022: € 336.9 m) driven by strong demand for base business and successful partnering activities; like-for-like revenue growth (excluding fx-effects and M&A effects) 14%Total EVT Execute revenues (incl. intersegment revenues) up 2% to € 356.6 m (H1 20

HAMBURG, GERMANY / ACCESSWIRE / August 22, 2023 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Conference call detailsDate: Tuesday, 29 August 2023Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT)To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.A simultaneous slide

JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULESJUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTIONTHE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBETHE PARTNERSHIP IS FOUNDED ON JUST - EVOTEC BIOLOGICS' AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ' LEADING BIOSIMILARS PIPELINE AND CAP

22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 MPOSITIVE MOMENTUM AND OUTLOOK FOR 2023DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRYHAMBURG, GERMANY / ACCESSWIRE / March 28, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(OTC:EVOTF)(NASDAQ:EVO) today reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.FINANCIALS REFLECT GREAT PERFORMANCEGroup revenues significantly exceeded the revenue target, up 22% to € 751.4 m (+15% like for like, excluding portfolio and fx effects (2021: € 618.0 m))Excellent base business up 30% to € 725.3 m in 2022Adjusted Group EBITDA a

HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(OTC:EVOTF)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.Conference call detailsDate: Tuesday, 28 March 2023 Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)To join via phone , please pre-register via the following link: https://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=7354164&linkSecurityString=94e63fcfcYou will then receive a confirmation email w

MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREASPARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGYCOMMERCIAL LAUNCH OF NEXT-GENERATION MULTI-OMICS DATA ANALYSIS PLATFORM PANHUNTERHAMBURG, GERMANY / ACCESSWIRE / November 9, 2022 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) today announced the financial results and corporate updates for the first nine months 2022.HIGHLIGHTSEVOTEC'S TOPLINE SUCCESS REFLECTS STRONG OVERALL DEMANDGroup revenues increased by 19% (13% excluding fx-effects) to € 510.8 m (9M 2021: € 431.0 m), despite significantly lower milestones, upfronts and license payments compared to a very strong comparable basis in 2021 (9M 2022:

HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.Conference call detailsDate: Wednesday, 09 November 2022Time: 02.00 pm CET (08.00 am EDT, 01.00 pm BST)To join via phone, please pre-register via the following link: http://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=8321512&linkSecurityString=9c554f538You will then receive a

BASE BUSINESS, NEW AND EXTENDED ALLIANCES DRIVE 24% GROWTHJUST - EVOTEC BIOLOGICS IN BUILD-UP PHASE - INVESTMENT ON TRACKACQUISITION EXPANDS CAPABILITIES AND EXPERTISE IN CELL THERAPYGUIDANCE FOR FULL-YEAR 2022 REFINEDHAMBURG, GERMANY / ACCESSWIRE / August 11, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF) today announced its financial results for the first half-year of 2022.HIGHLIGHTSEVOTEC CONTINUES ITS STRONG ORGANIC REVENUE GROWTH IN ALL BUSINESS AREASGroup revenues increased by 24% to € 336.9 m (H1 2021: € 271.3 m) driven by strong demand for its base business; like-for-like revenue growth (excluding fx-effects) 19%Continued strong revenue growth momentum: Tot

HAMBURG, GERMANY / ACCESSWIRE / August 4, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.Conference call detailsDate: Thursday, 11 August 2022Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)From Germany: +49 69 20 17 44 220From France: +33 170 709 502From Italy: +39 023 600 6663From UK: +44 20 3009 2470From USA: +1 877 423 0830Access Code: 37893553#A simultaneous slide presentation

Partnership Leverages Sernova's Proprietary Cell Pouch System™ with Evotec's iPSC-Based Insulin-Producing Beta CellsPartners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent DiabetesEvotec to Make Strategic Equity Investment of CAD $27 M / €20 M in SernovaSernova / Evotec Joint Conference Call and Webcast at 8:30 am EDT May 17, 2022 LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSXV:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, and Evotec SE ((FSE: EVT, NASDAQ:EVO), a global pharmaceutical and life science company, and leading develo

PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICETHE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF-THE-SHELF BETA CELL REPLACEMENT THERAPY FOR INSULIN-DEPENDENT DIABETESEVOTEC MAKES STRATEGIC € 20 M EQUITY INVESTMENT IN SERNOVAEVOTEC/SERNOVA JOINT CONFERENCE CALL AND WEBCAST AT 8.30 AM EDT MAY 17, 2022HAMBURG, GERMANY, and LONDON, ON / ACCESSWIRE / May 17, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) and Sernova Corp. (TSXV:SVA, OTCQB:SEOVF, FSE: PSH))), a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a

8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERSCOLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML-SUPPORTED DATA ANALYTICS$ 200 M UPFRONT AS WELL AS NEAR-TERM PERFORMANCE-BASED PAYMENTSDEAL POTENTIAL OF $ 5 BNHAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly p

HAMBURG, GERMANY / ACCESSWIRE / May 4, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.Conference call detailsDate: Wednesday, 11 May 2022 Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST) From Germany: +49 69 20 17 44 220From France: +33 170 709 502From Italy: +39 023 600 6663From UK: +44 20 3009 2470From USA: +1 877 423 0830Access Code: 53333776#A simultaneous slide presentation for participants dial

HAMBURG, GERMANY / ACCESSWIRE / April 5, 2022 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF); (NASDAQ:EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.Conference call detailsDate: Tuesday, 12 April 2022 Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST) From Germany: +49 69 20 17 44 220From France: +33 170 709 502From Italy: +39 023 600 6663From UK: +44 20 3009 2470From USA: +1 877 423 0830Access Code: 55886827#A simultaneous slide presentation for participants dialling in via phone